You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

49 Results
Guidelines and Advice
Status: Current
ID: PET 5
Jan 2009
Guidelines and Advice
Status: Current
ID: PET 3
Jan 2009
Guidelines and Advice
Mar 2009
Guidelines and Advice
Status: Archived
ID: 3-16
Jul 2009
Guidelines and Advice
Guidelines and Advice
Status: Current
ID: GL-C50-04-V2
Version: 2
Jan 2009
Guidelines and Advice
Jan 2009
Drug
Other Name(s): Cytosar®
Jul 2025
Drug
Other Name(s): Tasigna®
Jul 2025
Drug
Other Name(s): Tecentriq™
Jul 2025
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Exceptional Access Program
    lapatinib - Second-Line treatment of HER2 positive metastatic breast cancer in combination with chemotherapy after previous exposure to trastuzumab based treatments, with specific criteria
Exceptional Access Program
    lapatinib - Treatment of HER-2 positive metastatic breast cancer when used in combination with chemotherapy after use of trastuzumab in patients who have an adverse drug reaction or contraindication to trastuzumab therapy
Jul 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
Exceptional Access Program
    niLOtinib - Chronic phase Ph+ CML, with specific criteria
Exceptional Access Program
    niLOtinib - Accelerated phase Ph+ CML with documented resistance or intolerance to imatinib therapy, with specific criteria
Jul 2025

Pages